JS203 / Shanghai Junshi Biosci - LARVOL DELTA

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study (ASH 2025) - P1 | "To mitigate cytokine release syndrome, a single dose of rituximab(or biosimilar) was administered 3 days before the first dose of JS203 in the 2 highest dose groups. The median time toresponse were 2.2 months, 2.3 months and 2.2 months, respectively. The median progression-freesurvival and duration of response have not yet been reached.ConclusionsJS203 monotherapy demonstrated promising anti-tumor activity with high response rates and earlyresponses across different subtypes at the RP2D, and a tolerable safety profile."

Clinical • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting | N=219 ➔ 104 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment change • Enrollment closed • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P2 trial • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=219 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Trial completion date: Feb 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

JS203, a CD20×CD3 bispecific antibody with a 2:1 structure, demonstrated promising responses in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) in a phase I study (AACR 2025) - P1 | "JS203 SUD administration, when pretreated with rituximab, demonstrated a favorable safety profile and promising responses in patients with R/R B-NHL. CRS were mostly mild and primarily occurred in Cycle 1. Responses were observed even at very low dose levels and expansion at the 30 mg dose level is ongoing."

Clinical • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=219 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • IL10 • IL2 • IL6

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=219 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • IL10 • IL2 • IL6